fda crackdown on compounded semaglutide π¨ Moves to Shut Down Mass-Market GLP-1s The FDA is taking action to restrict widely marketed, nonβFDA-approved compounded GLP-1 products, citing concerns over safety, quality, and misleading claims. As demand The FDA is proposing the
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 11 - Aug 16




























